Sosei Group Corporation(SOLTF)
USD --+0.00%
Reward56Moderate
Risk64Medium-High
📊75%Data
Thin -42% profit margin · Revenue growing 13% YoY
SOLTF
+0.0 · +0.00%
USD · PINK
Sosei Group Corporation | Healthcare
Profitless Growth
Market Cap:497.04M
ℹ️
Reward Rating
56
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
64
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SOLTF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Sosei Group Corporation?

operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally.

SOLTF · Verdict

Solid reward · elevated risk

SOLTF stands out on growth and volatility, but watch the cash flow signal.

Based on 88% data coverage

SOLTF · Verdict

What’s working & what to watch

Strengths 2

  • Growth82/100

    Revenue +23.9% CAGR

  • Volatility75/100

    Above average

Watchouts 4

  • Cash flow16/100

    -11% free-cash-flow margin

  • Balance sheet26/100

    Current ratio 2.54

  • Profitability32/100

    -42% net margin · -19% ROE

  • Valuation33/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Sosei Group Corporation?

operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 497.04M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (56)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap497.04M
P/E RatioN/A
Dividend YieldN/A
52 Week High7.2
52 Week Low4.9
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding90M
No. of Employees382
IndustryBiotechnology
ExchangePINK
Beta-0.065
CurrencyUSD